Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 2
2014 1
2015 3
2016 4
2017 5
2018 3
2019 4
2020 5
2021 10
2022 13
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.
Izquierdo CP, Mingot-Castellano ME, Fuentes AEK, García-Arroba Peinado J, Cid J, Jimenez MM, Valcarcel D, Gómez-Seguí I, de la Rubia J, Martin P, Goterris R, Hernández L, Tallón I, Varea S, Fernández M, García-Muñoz N, Vara M, Zarzoso MF, García-Candel F, Paciello ML, García-García I, Zalba S, Campuzano V, Gala JM, Estévez JV, Jiménez GM, López Lorenzo JL, Arias EG, Freiría C, Solé M, Ávila Idrovo LF, Hernández Castellet JC, Cruz N, Lavilla E, Pérez-Montaña A, Atucha JA, Moreno Beltrán ME, Moreno Macías JR, Salinas R, Del Rio-Garma J. Izquierdo CP, et al. Blood Adv. 2022 Dec 27;6(24):6219-6227. doi: 10.1182/bloodadvances.2022008028. Blood Adv. 2022. PMID: 35930694 Free PMC article.

Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. ...The multivariate analysis showed that its use in the first 3 days after PEX was a

…

Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.

…
A systematic review of robotic breast surgery versus open surgery.
Maes-Carballo M, García-García M, Rodríguez-Janeiro I, Cámara-Martínez C, Alberca-Remigio C, Khan KS. Maes-Carballo M, et al. J Robot Surg. 2023 Dec;17(6):2583-2596. doi: 10.1007/s11701-023-01698-5. Epub 2023 Aug 25. J Robot Surg. 2023. PMID: 37624486 Review.

Nine of 16 (56.3%) were cohort studies, 2/16 (12.5%) RCTs, and 5/16 (31.3%) case-control studies. Taking p < 0.05 as the significance threshold, RABS versus CBS was better in aesthetic results and patient satisfaction (10/11 studies; 90%), was surgically costly (4/4 stu

…

Nine of 16 (56.3%) were cohort studies, 2/16 (12.5%) RCTs, and 5/16 (31.3%) case-control studies. Taking p < 0.05 as the significa

…
Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH, Nguyen V, Arnould L, Viola F, Zarranz-Ventura J, Barthelmes D, Creuzot-Garcher C, Gillies M; Fight Retinal Blindness! Study Group. Gabrielle PH, et al. Ophthalmol Retina. 2022 Nov;6(11):1044-1053. doi: 10.1016/j.oret.2022.05.008. Epub 2022 May 16. Ophthalmol Retina. 2022. PMID: 35589075 Free article.

The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patients (HR [95% CI] = 1.81 [1.21-3.62] for every decade increase in age, P < 0.01) were at a higher risk of RRD, whereas patients wit

…
The probability of RRD did not significantly increase at each successive injection (P = 0.95) with the time of follow-up. Older patie …
One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry.
Ortega-Paz L, Arévalos V, Fernández-Rodríguez D, Jiménez-Díaz V, Bañeras J, Campo G, Rodríguez-Santamarta M, Díaz JF, Scardino C, Gómez-Álvarez Z, Pernigotti A, Alfonso F, Amat-Santos IJ, Silvestro A, Rampa L, de la Torre Hernández JM, Bastidas G, Gómez-Lara J, Bikdeli B, García-García HM, Angiolillo DJ, Rodés-Cabau J, Sabaté M, Brugaletta S; CV COVID-19 registry investigators. Ortega-Paz L, et al. PLoS One. 2022 Dec 30;17(12):e0279333. doi: 10.1371/journal.pone.0279333. eCollection 2022. PLoS One. 2022. PMID: 36583998 Free PMC article.
COVID-19 cohort had higher rates of ATE (2.5% vs. 0.8%, HRadj 2.26 [1.02-4.99]; p = 0.044), VTE (3.7% vs. 0.4%, HRadj 9.33 [2.93-29.70]; p = 0.001), and serious cardiac arrhythmias (2.5% vs. 0.6%, HRadj 3.37 [1.35-8.46]; p = 0.010). During the post-acute phas …
COVID-19 cohort had higher rates of ATE (2.5% vs. 0.8%, HRadj 2.26 [1.02-4.99]; p = 0.044), VTE (3.7% vs. 0.4%, HRadj 9.33 [2.93-29.7 …
Prognostic Value of Microvascular Resistance at Rest in Patients With Takotsubo Syndrome.
Sans-Roselló J, Fernández-Peregrina E, Duran-Cambra A, Carreras-Mora J, Sionis A, Álvarez-García J, García-García HM. Sans-Roselló J, et al. JACC Cardiovasc Imaging. 2022 Oct;15(10):1784-1795. doi: 10.1016/j.jcmg.2022.03.030. Epub 2022 Jun 15. JACC Cardiovasc Imaging. 2022. PMID: 36125887 Free article.
Kaplan-Meier curves showed higher rates of MACE in patients with higher NH-IMRangio (28.9% vs 13.3%; P = 0.019) and in those with 3 coronary arteries with increased MR compared to those with 2 or 1 affected arteries (33.3% vs 15.9% vs 9.5%; P = 0.040 and P = …
Kaplan-Meier curves showed higher rates of MACE in patients with higher NH-IMRangio (28.9% vs 13.3%; P = 0.019) and in those with 3 c …
Association between telomere length, frailty and death in older adults.
El Assar M, Angulo J, Carnicero JA, Walter S, García-García FJ, Rodríguez-Artalejo F, Rodríguez-Mañas L. El Assar M, et al. Geroscience. 2021 Apr;43(2):1015-1027. doi: 10.1007/s11357-020-00291-0. Epub 2020 Nov 15. Geroscience. 2021. PMID: 33190211 Free PMC article.
Finally, while frailty at baseline was significantly associated with higher risk of death at follow-up (OR: 4.08 [1.97-8.43], p < 0.001), TL did not significantly change the mortality risk (OR: 1.05 [0.94-1.16]). ...
Finally, while frailty at baseline was significantly associated with higher risk of death at follow-up (OR: 4.08 [1.97-8.43], p < …
Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir.
Ortiz-Gracia A, Ríos M, Tobías E, Noguera-Julian A, García-García FJ, Cantó-Santos J, Valls-Roca L, Garrabou G, Grau JM, Cardellach F, Sánchez E, Morén C, Fortuny C. Ortiz-Gracia A, et al. Arch Dis Child. 2022 Jul;107(7):686-691. doi: 10.1136/archdischild-2021-322996. Epub 2022 Mar 14. Arch Dis Child. 2022. PMID: 35288419 Free PMC article. Clinical Trial.
RESULTS: Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valganciclovir compared with controls (p>0.05 in all cases). CONCLUSIONS: No evidence of mitochondrial toxicity was found in infants t …
RESULTS: Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valg …
Influence of the degree of anaemia on the prognosis of older adults with heart failure (SPAN-HF study).
Grau Amorós J, García García JÁ, Mira Escartí JA, Serrado Iglesias A, Moreno García MC, Manzano L, Quesada Simón MA, Dávila Ramos MF, Casado Cerrada J, González Franco Á, Montero-Pérez-Barquero M; en representación de los investigadores del Grupo RICA. Grau Amorós J, et al. Med Clin (Barc). 2022 Feb 25;158(4):167-172. doi: 10.1016/j.medcli.2021.01.016. Epub 2021 May 4. Med Clin (Barc). 2022. PMID: 33962767 English, Spanish.
We recorded a total of 768 deaths and readmissions. There were 23 (4%), 12 (4%) and 49 (9.2%), (p=.001) individuals who died due to HF and 154 (27%), 73 (24%) and 193 (36%) (P<.001) admissions for this pathology, respectively. Patients with persistent anaemia had …
We recorded a total of 768 deaths and readmissions. There were 23 (4%), 12 (4%) and 49 (9.2%), (p=.001) individuals who died due to H …
Risk factors and outcome of COVID-19 in patients with hematological malignancies.
Piñana JL, Martino R, García-García I, Parody R, Morales MD, Benzo G, Gómez-Catalan I, Coll R, De La Fuente I, Luna A, Merchán B, Chinea A, de Miguel D, Serrano A, Pérez C, Diaz C, Lopez JL, Saez AJ, Bailen R, Zudaire T, Martínez D, Jurado M, Calbacho M, Vázquez L, Garcia-Cadenas I, Fox L, Pimentel AI, Bautista G, Nieto A, Fernandez P, Vallejo JC, Solano C, Valero M, Espigado I, Saldaña R, Sisinni L, Ribera JM, Jimenez MJ, Trabazo M, Gonzalez-Vicent M, Fernández N, Talarn C, Montoya MC, Cedillo A, Sureda A; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Piñana JL, et al. Exp Hematol Oncol. 2020 Aug 25;9:21. doi: 10.1186/s40164-020-00177-z. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32864192 Free PMC article.
Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [ …
Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02 …
48 results